[Blocker of angiotensin-1 receptor antagonist losartan. Part III. Experience in therapy for chronic heart failure and after acute myocardial infarction].
This is the third part in a series of papers dealing with various aspects of clinical pharmacology of the first AT(1)-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction. This part contains review of literature data concerning the use of losartan for the treatment of chronic heart failure and high risk patients after myocardial infarction. Efficacy and safety of losartan in these conditions was demonstrated in two major randomized trials. In one of these trials effects of the drug were studied in patients with chronic heart failure and in the second one therapy with losartan was started in acute period of myocardial infarction.
Sidorenko
B A
BA
Preobrazhenskiĭ
D V
DV
Stetsenko
T M
TM
Tarykina
E V
EV
Tsurko
V V
VV
D000803:Angiotensin I; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D019808:Losartan / Q000009:adverse effects / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D000803:Angiotensin I; D019808:Losartan